-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Downgrades Sionna Therapeutics to Neutral

Benzinga·08/11/2026 14:17:26
Listen to the news
Guggenheim analyst Yatin Suneja downgrades Sionna Therapeutics (NASDAQ:SION) from Buy to Neutral.